Detalle Publicación

Engineering anti-myeloma responses using affinity-enhanced TCR-Engineered T cells

Título de la revista: CANCER CELL
ISSN: 1535-6108
Volumen: 28
Número: 3
Páginas: 281 - 283
Fecha de publicación: 2015
NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.